Tuesday, March 19, the FDA approved Zulresso (brexanolone) injection for intravenous (IV) use to treat post-partum depression (PPD) in adult women. No other drug before now has been approved to specifically treat PPD. Zulresso will be available through Risk Evaluation and Mitigation Strategy (REMS) Program that requires the drug to be administered by a health care provider in certified health care facilities due to concerns about serious risks such as excessive sedation, or sudden loss of consciousness.
Read the Full FDA Press Release Here.
[elfsight_social_share_buttons id=”3″]